Loading
Some cancers raise the calcium level in the blood. It causes thirst, passing a lot of urine, constipation, sickness, tiredness and confusion, and can be dangerous. A blood test confirms it. Treatment is a drip of fluid, then a medicine that stops calcium leaving the bones (a bisphosphonate such as zoledronic acid, or denosumab), alongside treatment of the cancer itself.
Society for Endocrinology 2016: measure calcium adjusted for albumin. Under 3.0 mmol/L is often asymptomatic; 3.0 to 3.5 usually needs prompt treatment; over 3.5 needs urgent correction for the risk of dysrhythmia and coma. Check phosphate, PTH, urea and electrolytes and an ECG for a short QT; high calcium with a low PTH points to malignancy. Review drugs and supplements. Rehydrate with intravenous 0.9% saline, 4 to 6 L over 24 hours, watching for fluid overload in the elderly or with renal impairment; loop diuretics do not lower calcium and are only for overload. Then an intravenous bisphosphonate: zoledronic acid 4 mg over 15 minutes, pamidronate 30 to 90 mg or ibandronic acid 2 to 4 mg, more slowly and at reduced dose in renal impairment; the calcium nadir comes at 2 to 4 days. Prednisolone 40 mg daily for lymphoma and other calcitriol-driven causes. Denosumab, calcitonin and calcimimetics under specialist supervision.
Endocrine Society 2023 (GRADE): treat with denosumab or an intravenous bisphosphonate (strong recommendation); suggests denosumab rather than an intravenous bisphosphonate, calcitonin with a bisphosphonate or denosumab for severe hypercalcaemia, denosumab for refractory or recurrent cases despite bisphosphonate, an antiresorptive added to glucocorticoids for calcitriol-driven tumours, and a calcimimetic or antiresorptive for parathyroid carcinoma (all conditional, low certainty). Treating the cancer is what controls hypercalcaemia and prevents recurrence.
Why: The symptoms are vague and easily put down to the cancer or its treatment.
“Polyuria and thirst Anorexia, nausea and constipation Mood disturbance, cognitive dysfunction, confusion and coma”
Why: Low albumin, common in cancer, hides a high free calcium; a low PTH with high calcium points to the cancer as the cause.
“Serum calcium is bound to albumin, and measurements should be adjusted for serum albumin.”
Why: At that level the risk of heart rhythm problems and coma is high.
“>3.5 mmol/L: requires urgent correction due to the risk of dysrhythmia and coma”
Why: High calcium affects the heart's electrical activity.
“Look for shortened QT interval or other conduction abnormalities”
Why: Thiazides, lithium, calcium and vitamin D supplements can add to the problem.
“Drugs including supplements and over-the-counter preparations”
Why: High calcium makes the kidneys lose water, and dehydration in turn stops them clearing calcium.
“Intravenous 0.9% saline 4–6 L in 24 h Monitor for fluid overload if renal impairment or elderly”
Why: They do not reduce calcium and can worsen dehydration.
“Loop diuretics rarely used and only if fluid overload develops; not effective for reducing serum calcium”
Why: These stop bone releasing calcium; the Endocrine Society makes this its one strong recommendation.
“The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP).”
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 · strong recommendation
Why: Bisphosphonates are cleared by the kidneys and can damage them if given too fast.
“Give more slowly and consider dose reduction in renal impairment”
Why: Calcitonin works within hours, while bisphosphonates and denosumab take days.
“The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory/recurrent HCM despite treatment with BP, the use of Dmab.”
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 · conditional recommendation, low certainty of evidence
Why: Steroids switch off the excess vitamin D production these tumours cause.
“Glucocorticoids (inhibit 1,25OHD production) In lymphoma, other granulomatous diseases or 25OHD poisoning Prednisolone 40 mg daily”
Why: Overshoot is possible, especially with vitamin D deficiency or a suppressed PTH.
“Monitor serum calcium response: will reach nadir at 2–4 days Can cause hypocalcaemia if vitamin D deficiency or suppressed PTH”
Why: Lowering calcium buys time; treating the cancer is what keeps it down.
“Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence.”
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Both sources start with assessment and intravenous saline and then an antiresorptive. They differ on which one: the Endocrine Society 2023 recommends denosumab or an intravenous bisphosphonate (strong) and suggests denosumab rather than a bisphosphonate (conditional, low certainty), while the Society for Endocrinology 2016 emergency guidance gives an intravenous bisphosphonate first and keeps denosumab, calcitonin and calcimimetics for specialists when the response is poor. The Endocrine Society also suggests calcitonin with the antiresorptive for severe hypercalcaemia. Saline volumes, the bisphosphonate doses and the warning against loop diuretics come from the Society for Endocrinology; the Endocrine Society's full text, which may give its own, could not be read.
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 · Society for Endocrinology, Endocrine Connections 2016
Where it differs: Suggests denosumab rather than an intravenous bisphosphonate for hypercalcaemia of malignancy, and denosumab for cases refractory or recurrent despite a bisphosphonate.
Evidence: Conditional recommendation, low certainty (GRADE).
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023
Where it differs: Uses zoledronic acid, pamidronate or ibandronic acid after saline, and lists denosumab, calcitonin and calcimimetics as second-line treatments under specialist supervision.
Evidence: Expert emergency guidance, not graded.
Where it differs: Treats hypercalcaemia from parathyroid carcinoma with either a calcimimetic or an antiresorptive.
Evidence: Conditional recommendation, low certainty (Endocrine Society 2023).
Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Treat with denosumab or an intravenous bisphosphonate | strong recommendation | Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 |
| Denosumab rather than an intravenous bisphosphonate | conditional, low certainty | Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 |
| Calcitonin with a bisphosphonate or denosumab for severe hypercalcaemia | conditional, low certainty | Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 |
| Denosumab for hypercalcaemia refractory or recurrent despite a bisphosphonate | conditional, low certainty | Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 |
| Add an antiresorptive to glucocorticoids for calcitriol-driven tumours with persistent severe hypercalcaemia “The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM.” | conditional, low certainty | Endocrine Society, Journal of Clinical Endocrinology and Metabolism 2023 |
Shares the tags protocol, acute-oncology, oncological-emergency, metabolic.
Shares Bone metastases and skeletal-related events and the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares Pamidronate, Denosumab, Zoledronic acid.
Shares the tags protocol, acute-oncology, oncological-emergency.
Shares the tags protocol, acute-oncology, oncological-emergency.